Exciting progress for our "sister company" InCarda Therapeutics! #AtrialFibrillation remains an enormous unmet need, and the potential to intervene early to stop episodes as soon as they start could dramatically change disease progression over time, including reducing stroke risk and risk of more severe heart disease. Women in particular often don't get the care they need when they present with symptoms. Inaya technology was co-invented by a former InCarda team and uses some of the same fundamental groundbreaking formulation technology in other cardiovascular indications. The Inaya team will be cheering them on in their next exciting steps! #patientsfirst #atrialfibrillation #stopAF #hearthealth #womensheart
Things are happening at InCarda!!! Read all about it: https://lnkd.in/gFUX8e2D Analysis of the results of the RESTORE-1 Phase 3 trial following its premature termination demonstrated statistically significant cardioversion of PAF with orally inhaled flecainide, providing compelling?rationale for the continued development of FlecIH-103 in the target population of PAF patients. —?The RESTORE-1 trial was stopped prematurely due to lower-than-expected efficacy and plasma flecainide levels during a blinded review of the data —?There were no safety concerns associated with the administration of FlecIH-103 A novel drug delivery platform has shown the potential to enable efficient and reliable delivery of flecainide to the heart through the lung, appropriate for both hospital and home use Bridging Phase 1 study data to date establishes a path for future registration trials